The relationship between ERCC1 expression levels and cisplatin sensitivity has been corroborated by several retrospective clinical studies that report altered expression levels of ERCC1 in patients with NSCLC and other cancers suggesting that ERCC1/XPF could be a potential therapeutic target to enhance platinum response in several tumor types [7,10,11,12,13,14,15]. The gene discussed is ERCC4; the disease is cancer.